Developer docs
API playgroundTry for free, no card

Search company profiles

Melinta Therapeutics

Full company profile

uuid0002d3p

Namestring
Melinta Therapeutics
Legal namestring
Melinta Therapeutics, LLC
Websiteurl
melinta.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Melinta Therapeutics, LLC is a commercial-stage biopharmaceutical company that develops, markets, and distributes anti-infective therapeutics targeting acute and life-threatening infections. The company's portfolio comprises seven FDA-approved products: REZZAYO (rezafungin for injection), a once-weekly echinocandin antifungal for candidemia and invasive candidiasis; VABOMERE (meropenem and vaborbactam), a carbapenem plus beta-lactamase inhibitor combination for carbapenem-resistant Enterobacteriaceae; BAXDELA (delafloxacin), a fluoroquinolone for acute bacterial skin and skin structure infections; KIMYRSA and ORBACTIV (oritavancin), single-dose lipoglycopeptide antibiotics for ABSSSI; MINOCIN (minocycline) for Injection, an intravenous tetracycline; and TOPROL-XL (metoprolol succinate), a cardiovascular beta-blocker. The company also held U.S. commercialization rights to the investigational beta-lactam/BLI combination cefepime-taniborbactam licensed from Venatorx Pharmaceuticals.

The business sells primarily into U.S. hospitals, hospital systems, specialty pharmacies, and home infusion providers through an enterprise field sales motion and formulary adoption. International distribution is executed via channel partnerships with Eurofarma, Hikma, Menarini, and Xediton in select regions. Development-stage funding includes a multi-year BARDA partnership that delivered an initial $20.5 million award in July 2023 with potential expansion to $141.9 million for supplemental antibiotic indications, including pediatric and biothreat applications. Under Deerfield Management ownership from 2020, the company reportedly delivered 85% cumulative revenue growth, positive cash flow, and sustainable profitability.

In August 2025, CorMedix Inc. acquired Melinta for $300 million ($260M cash plus $40M CorMedix equity), with up to $25 million in FDA milestone payments tied to REZZAYO prophylaxis approval and tiered royalties. The transaction closed in September 2025, transforming Melinta into a wholly-owned subsidiary of CorMedix. The company's headquarters were located in Parsippany, New Jersey with a second office in Lake Forest, Illinois.

Short descriptiontext

Melinta Therapeutics is a commercial-stage biopharmaceutical company that markets a portfolio of seven FDA-approved anti-infective drugs, including REZZAYO, VABOMERE, BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, and TOPROL-XL, sold primarily to U.S. hospitals and acute care settings. Following its August 2025 acquisition by CorMedix for $300 million, it operates as a wholly-owned subsidiary.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-infective pharmaceuticals, hospital antibiotics, antifungal therapies, acute care therapeutics, infectious disease treatments
Industry1 code
SECONDARYHLAIACAG
Cardiology & Vascular Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-Infective Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue generated from sales of commercial-stage anti-infective products including REZZAYO, MINOCIN, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL. Products sold to hospitals, healthcare providers, and through specialty pharmacies.

ng.investing.com
2BARDA Funding
TypeLicensing Royalties
Description

Government funding from Biomedical Advanced Research and Development Authority (BARDA) to advance FDA-approved antibiotic candidates through supplemental new drug applications, with initial funding of $20.5 million and potential up to $141.9 million.

openpr.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Melinta Therapeutics develops, manufactures, and commercializes a portfolio of seven FDA-approved anti-infective pharmaceutical products, including antibiotics (BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, VABOMERE), a once-weekly echinocandin antifungal (REZZAYO), and a cardiovascular beta-blocker (TOPROL-XL), plus the investigational cefepime-taniborbactam licensed from Venatorx. Products are sold to hospitals, healthcare providers, and specialty/home infusion channels in the US and through international distribution partners, targeting acute, life-threatening bacterial and fungal infections including drug-resistant pathogens.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 85% revenue growth achieved from 2020 to 2025 under Deerfield ownership
+2 more records
Product overview1 text field

Melinta Therapeutics is a commercial-stage pharmaceutical company providing innovative therapies for acute and life-threatening illnesses. The company's portfolio consists of seven commercial-stage products: BAXDELA (delafloxacin), KIMYRSA (oritavancin), MINOCIN (minocycline) for Injection, ORBACTIV (oritavancin), REZZAYO (rezafungin for injection), TOPROL-XL (metoprolol succinate), and VABOMERE (meropenem and vaborbactam). These products focus on anti-infective treatments for acute care settings including antibiotics for skin infections, urinary tract infections, and serious hospital-acquired infections, as well as an antifungal and a cardiovascular product. The company also holds U.S. commercial rights to the investigational antibiotic cefepime-taniborbactam from Venatorx Pharmaceuticals.

Product and service8 records
1REZZAYO (rezafungin for injection)
CategoryAntifungal pharmaceutical
Description

Novel once-weekly echinocandin antifungal approved for treatment of candidemia and invasive candidiasis in adults; currently in Phase III trials for prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplant patients. Marketed in the U.S. by Melinta under license from Mundipharma.

2KIMYRSA (oritavancin)
CategoryAntibiotic pharmaceutical
Description

Single-dose lipoglycopeptide antibiotic for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.

3VABOMERE (meropenem and vaborbactam)
CategoryAntibiotic pharmaceutical
Description

Carbapenem antibiotic combination with beta-lactamase inhibitor for treatment of complicated urinary tract infections and carbapenem-resistant Enterobacteriaceae (CRE) infections.

4ORBACTIV (oritavancin)
CategoryAntibiotic pharmaceutical
Description

Lipoglycopeptide antibiotic with long half-life providing single-dose treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.

5MINOCIN (minocycline) for Injection
CategoryAntibiotic pharmaceutical
Description

Intravenous tetracycline antibiotic for treatment of serious infections caused by susceptible organisms in hospital settings.

6BAXDELA (delafloxacin)
CategoryAntibiotic pharmaceutical
Description

Fluoroquinolone antibiotic with broad-spectrum activity for treatment of acute bacterial skin and skin structure infections (ABSSSI).

7TOPROL-XL (metoprolol succinate)
CategoryCardiovascular pharmaceutical
Description

Beta-blocker cardiovascular product for treatment of hypertension, angina, and heart failure.

8Cefepime-taniborbactam
CategoryInvestigational antibiotic pharmaceutical
Description

Investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) combination antibiotic licensed from Venatorx Pharmaceuticals in 2023 for U.S. commercialization. Under FDA review for complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2024-12-01
Description

Melinta joined NHIA's Future of Infusion Advisory Council (FIAC), a strategic advisory group addressing critical issues and opportunities in the home and alternate site infusion industry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-01
Description

Exclusive license agreement for U.S. commercialization of cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections and hospital-acquired bacterial pneumonia.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

Partnership with BARDA secured initial $20.5 million in funding with potential to reach $141.9 million to advance FDA-approved antibiotic candidates through supplemental new drug applications. Also includes development of products for pediatric use and biothreat pathogens.

4Eurofarma
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner for delafloxacin in global markets outside the U.S.

melinta.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam in their territories.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam in Europe, Middle East, and other regions.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

International distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Licensing partner for rezafungin (REZZAYO) in the U.S. Melinta holds exclusive rights to commercialize rezafungin in the U.S. from Mundipharma. Joint development of Rezzayo for prophylaxis indications.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global Japanese pharmaceutical company with a strong anti-infective franchise including cefiderocol (FETROJA). Comparable as a broader anti-infective portfolio player with hospital-channel focus.

TypeDirect peer
Description

Developer of eravacycline (XERAVA), a fluorocycline antibiotic for complicated intra-abdominal and urinary tract infections — a direct therapeutic-area competitor within the hospital anti-infective space.

3Nabriva Therapeutics
TypeDirect peer
Description

Specialty anti-infective company commercializing lefamulin (XENLETA), a pleuromutilin antibiotic for community-acquired bacterial pneumonia. Closely aligned hospital/outpatient anti-infective commercial model.

TypeBroad incumbent
Description

Diversified global pharmaceutical company with a significant hospital anti-infective portfolio. Relevant broad incumbent competitor and partner in the anti-infective therapeutics space.

TypeEmerging player
Description

Clinical-stage developer of cefepime-taniborbactam, the beta-lactam/BLI combination licensed to Melinta. Comparable by therapeutic focus on resistant gram-negative infections and direct partnership overlap.

TypeDirect peer
Description

Developer of ibrexafungerp (BREXAFEMME), a novel antifungal for vulvovaginal candidiasis and invasive Candida infections. A direct peer in the hospital antifungal specialty space adjacent to REZZAYO.

TypeDirect peer
Description

Specialty antibiotic company focused on tetracycline-class antibiotics (omadacycline/NUZYRA) for community-acquired and skin infections. Directly comparable as a hospital/anti-infective specialty pharma targeting resistant pathogens.

TypeOthers
Description

Former specialty antibiotics company (plazomicin/ZEMDRI) that serves as a cautionary comparable for the hospital anti-infective commercial model, given its post-launch commercial challenges and ultimate restructuring.

TypeBroad incumbent
Description

Major pharmaceutical company with established hospital anti-infective products including ZERBAXA (ceftolozane/tazobactam). Comparable as a broad incumbent in the hospital anti-infective category.

TypeDirect peer
Description

Clinical-stage anti-infective company developing antifungal and antibacterial therapies, including rezafungin-related echinocandins. Closely comparable mechanism and indication overlap with Melinta's REZZAYO franchise.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Melinta Therapeutics

Anti-Infective Pharmaceuticalsmelinta.com

Melinta Therapeutics is a commercial-stage biopharmaceutical company that markets a portfolio of seven FDA-approved anti-infective drugs, including REZZAYO, VABOMERE, BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, and TOPROL-XL, sold primarily to U.S. hospitals and acute care settings. Following its August 2025 acquisition by CorMedix for $300 million, it operates as a wholly-owned subsidiary.

What Melinta Therapeutics does

Melinta Therapeutics, LLC is a commercial-stage biopharmaceutical company that develops, markets, and distributes anti-infective therapeutics targeting acute and life-threatening infections. The company's portfolio comprises seven FDA-approved products: REZZAYO (rezafungin for injection), a once-weekly echinocandin antifungal for candidemia and invasive candidiasis; VABOMERE (meropenem and vaborbactam), a carbapenem plus beta-lactamase inhibitor combination for carbapenem-resistant Enterobacteriaceae; BAXDELA (delafloxacin), a fluoroquinolone for acute bacterial skin and skin structure infections; KIMYRSA and ORBACTIV (oritavancin), single-dose lipoglycopeptide antibiotics for ABSSSI; MINOCIN (minocycline) for Injection, an intravenous tetracycline; and TOPROL-XL (metoprolol succinate), a cardiovascular beta-blocker. The company also held U.S. commercialization rights to the investigational beta-lactam/BLI combination cefepime-taniborbactam licensed from Venatorx Pharmaceuticals.

The business sells primarily into U.S. hospitals, hospital systems, specialty pharmacies, and home infusion providers through an enterprise field sales motion and formulary adoption. International distribution is executed via channel partnerships with Eurofarma, Hikma, Menarini, and Xediton in select regions. Development-stage funding includes a multi-year BARDA partnership that delivered an initial $20.5 million award in July 2023 with potential expansion to $141.9 million for supplemental antibiotic indications, including pediatric and biothreat applications. Under Deerfield Management ownership from 2020, the company reportedly delivered 85% cumulative revenue growth, positive cash flow, and sustainable profitability.

In August 2025, CorMedix Inc. acquired Melinta for $300 million ($260M cash plus $40M CorMedix equity), with up to $25 million in FDA milestone payments tied to REZZAYO prophylaxis approval and tiered royalties. The transaction closed in September 2025, transforming Melinta into a wholly-owned subsidiary of CorMedix. The company's headquarters were located in Parsippany, New Jersey with a second office in Lake Forest, Illinois.

Melinta Therapeutics firmographics

Firmographics
Name
Melinta Therapeutics
Legal name
Melinta Therapeutics, LLC
Website
https://melinta.com
Company type
Private
Founded year
2017
Operating status
Acquired
Headcount range
51–100 employees
Short description
Melinta Therapeutics is a commercial-stage biopharmaceutical company that markets a portfolio of seven FDA-approved anti-infective drugs, including REZZAYO, VABOMERE, BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, and TOPROL-XL, sold primarily to U.S. hospitals and acute care settings. Following its August 2025 acquisition by CorMedix for $300 million, it operates as a wholly-owned subsidiary.
Ownership category
akta.pro rank

Where Melinta Therapeutics is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Melinta Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. Pharmaceutical Product Sales: Revenue generated from sales of commercial-stage anti-infective products including REZZAYO, MINOCIN, VABOMERE, KIMYRSA, ORBACTIV, BAXDELA, and TOPROL-XL. Products sold to hospitals, healthcare providers, and through specialty pharmacies.
  2. BARDA Funding: Government funding from Biomedical Advanced Research and Development Authority (BARDA) to advance FDA-approved antibiotic candidates through supplemental new drug applications, with initial funding of $20.5 million and potential up to $141.9 million.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Melinta Therapeutics product offering

Product offering

Core offering

Melinta Therapeutics develops, manufactures, and commercializes a portfolio of seven FDA-approved anti-infective pharmaceutical products, including antibiotics (BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, VABOMERE), a once-weekly echinocandin antifungal (REZZAYO), and a cardiovascular beta-blocker (TOPROL-XL), plus the investigational cefepime-taniborbactam licensed from Venatorx. Products are sold to hospitals, healthcare providers, and specialty/home infusion channels in the US and through international distribution partners, targeting acute, life-threatening bacterial and fungal infections including drug-resistant pathogens.

Product overview

Melinta Therapeutics is a commercial-stage pharmaceutical company providing innovative therapies for acute and life-threatening illnesses. The company's portfolio consists of seven commercial-stage products: BAXDELA (delafloxacin), KIMYRSA (oritavancin), MINOCIN (minocycline) for Injection, ORBACTIV (oritavancin), REZZAYO (rezafungin for injection), TOPROL-XL (metoprolol succinate), and VABOMERE (meropenem and vaborbactam). These products focus on anti-infective treatments for acute care settings including antibiotics for skin infections, urinary tract infections, and serious hospital-acquired infections, as well as an antifungal and a cardiovascular product. The company also holds U.S. commercial rights to the investigational antibiotic cefepime-taniborbactam from Venatorx Pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Products and services

  • REZZAYO (rezafungin for injection) Novel once-weekly echinocandin antifungal approved for treatment of candidemia and invasive candidiasis in adults; currently in Phase III trials for prophylaxis of invasive fungal diseases in allogeneic hematopoietic stem cell transplant patients. Marketed in the U.S. by Melinta under license from Mundipharma.
  • KIMYRSA (oritavancin) Single-dose lipoglycopeptide antibiotic for treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.
  • VABOMERE (meropenem and vaborbactam) Carbapenem antibiotic combination with beta-lactamase inhibitor for treatment of complicated urinary tract infections and carbapenem-resistant Enterobacteriaceae (CRE) infections.
  • ORBACTIV (oritavancin) Lipoglycopeptide antibiotic with long half-life providing single-dose treatment of acute bacterial skin and skin structure infections (ABSSSI) in adult patients.
  • MINOCIN (minocycline) for Injection Intravenous tetracycline antibiotic for treatment of serious infections caused by susceptible organisms in hospital settings.
  • BAXDELA (delafloxacin) Fluoroquinolone antibiotic with broad-spectrum activity for treatment of acute bacterial skin and skin structure infections (ABSSSI).
  • TOPROL-XL (metoprolol succinate) Beta-blocker cardiovascular product for treatment of hypertension, angina, and heart failure.
  • Cefepime-taniborbactam Investigational beta-lactam/beta-lactamase inhibitor (BL/BLI) combination antibiotic licensed from Venatorx Pharmaceuticals in 2023 for U.S. commercialization. Under FDA review for complicated urinary tract infections (cUTI) and hospital-acquired bacterial pneumonia.

Quantifiable outcome

  • 85% revenue growth achieved from 2020 to 2025 under Deerfield ownership
  • +2 more outcomes

Companies that use Melinta Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Melinta Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Melinta Therapeutics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered minor and core.

  • National Home Infusion Association (NHIA)minorGTM or Marketing Partner · 1 December 2024Melinta joined NHIA's Future of Infusion Advisory Council (FIAC), a strategic advisory group addressing critical issues and opportunities in the home and alternate site infusion industry.
  • Venatorx PharmaceuticalscoreStrategic or Co-development Partner · 1 November 2023Exclusive license agreement for U.S. commercialization of cefepime-taniborbactam, a beta-lactam/beta-lactamase inhibitor combination antibiotic for complicated urinary tract infections and hospital-acquired bacterial pneumonia.
  • BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 1 July 2023Partnership with BARDA secured initial $20.5 million in funding with potential to reach $141.9 million to advance FDA-approved antibiotic candidates through supplemental new drug applications. Also includes development of products for pediatric use and biothreat pathogens.
  • EurofarmaminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin in global markets outside the U.S.
  • HikmaminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam in their territories.
  • MenariniminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam in Europe, Middle East, and other regions.
  • XeditonminorChannel Partner/ Reseller/ DistributorInternational distribution partner for delafloxacin, oritavancin, meropenem and vaborbactam.
  • MundipharmacoreStrategic or Co-development PartnerLicensing partner for rezafungin (REZZAYO) in the U.S. Melinta holds exclusive rights to commercialize rezafungin in the U.S. from Mundipharma. Joint development of Rezzayo for prophylaxis indications.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Melinta Therapeutics competitors and assessment

Company assessment

Broad incumbents

  • Shionogi: Global Japanese pharmaceutical company with a strong anti-infective franchise including cefiderocol (FETROJA). Comparable as a broader anti-infective portfolio player with hospital-channel focus.
  • Pfizer: Diversified global pharmaceutical company with a significant hospital anti-infective portfolio. Relevant broad incumbent competitor and partner in the anti-infective therapeutics space.
  • Merck & Co. Major pharmaceutical company with established hospital anti-infective products including ZERBAXA (ceftolozane/tazobactam). Comparable as a broad incumbent in the hospital anti-infective category.

Direct peers

  • Tetraphase Biosciences: Developer of eravacycline (XERAVA), a fluorocycline antibiotic for complicated intra-abdominal and urinary tract infections — a direct therapeutic-area competitor within the hospital anti-infective space.
  • Nabriva Therapeutics: Specialty anti-infective company commercializing lefamulin (XENLETA), a pleuromutilin antibiotic for community-acquired bacterial pneumonia. Closely aligned hospital/outpatient anti-infective commercial model.
  • Scynexis: Developer of ibrexafungerp (BREXAFEMME), a novel antifungal for vulvovaginal candidiasis and invasive Candida infections. A direct peer in the hospital antifungal specialty space adjacent to REZZAYO.
  • Paratek Pharmaceuticals: Specialty antibiotic company focused on tetracycline-class antibiotics (omadacycline/NUZYRA) for community-acquired and skin infections. Directly comparable as a hospital/anti-infective specialty pharma targeting resistant pathogens.
  • Cidara Therapeutics: Clinical-stage anti-infective company developing antifungal and antibacterial therapies, including rezafungin-related echinocandins. Closely comparable mechanism and indication overlap with Melinta's REZZAYO franchise.

Emerging players

  • Venatorx Pharmaceuticals: Clinical-stage developer of cefepime-taniborbactam, the beta-lactam/BLI combination licensed to Melinta. Comparable by therapeutic focus on resistant gram-negative infections and direct partnership overlap.

Others

  • Achaogen: Former specialty antibiotics company (plazomicin/ZEMDRI) that serves as a cautionary comparable for the hospital anti-infective commercial model, given its post-launch commercial challenges and ultimate restructuring.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Melinta Therapeutics social profiles

Digital presence

Melinta Therapeutics compliance and trust

Trust signal

Compliance2 records

Melinta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Melinta Therapeutics leadership team

Management profile

Number of profiles

Profiles14 records

Melinta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Melinta Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Melinta Therapeutics

What does Melinta Therapeutics do?

Melinta Therapeutics develops, manufactures, and commercializes a portfolio of seven FDA-approved anti-infective pharmaceutical products, including antibiotics (BAXDELA, KIMYRSA, ORBACTIV, MINOCIN, VABOMERE), a once-weekly echinocandin antifungal (REZZAYO), and a cardiovascular beta-blocker (TOPROL-XL), plus the investigational cefepime-taniborbactam licensed from Venatorx. Products are sold to hospitals, healthcare providers, and specialty/home infusion channels in the US and through international distribution partners, targeting acute, life-threatening bacterial and fungal infections including drug-resistant pathogens.

Is Melinta Therapeutics a public or private company?

Melinta Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Melinta Therapeutics founded?

Melinta Therapeutics was founded in 2017. It employs 51 to 100 people.

Where is Melinta Therapeutics based?

Melinta Therapeutics is headquartered in Parsippany, United States, in the North America region.

How does Melinta Therapeutics make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are BARDA Funding.

Who are Melinta Therapeutics's main competitors?

Broad incumbents on record are Shionogi, Pfizer and Merck & Co.. Direct peers are Tetraphase Biosciences, Nabriva Therapeutics, Scynexis, Paratek Pharmaceuticals and Cidara Therapeutics. Venatorx Pharmaceuticals is listed as an emerging player. Achaogen is listed as an others.

Does Melinta Therapeutics have an API?

No public API is recorded for Melinta Therapeutics.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Urology TimesFDA requests additional data regarding cefepime-taniborbactam for cUTIThe FDA issued a complete response letter to Venatorx Pharmaceuticals and Melinta Therapeutics regarding their new drug application for cefepime-taniborbactam, requesting additional chemistry, manufacturing, and controls data. The agency did not identify clinical or safety issues with the treatment, nor did it require new clinical trials. Both companies expressed disappointment but remain confident in generating the requested data to advance approval.Quiver QuantitativeCorMedix Q2 Revenue Reaches $101.9 Million as Net Income Hits $26.0 Million | CRMD Stock NewsCorMedix Therapeutics reported second-quarter 2026 consolidated revenue of $101.9 million and net income of $26.0 million, driven by sales from its DefenCath product and the acquired Melinta portfolio. The company raised its full-year adjusted EBITDA guidance to $125–$140 million while maintaining its full-year revenue outlook of $325–$345 million.AInvestCormedix raises FY adjusted EBITDA guidance to $125M to $140MCorMedix Inc. raised its full-year 2026 adjusted EBITDA guidance to $115 million–$135 million, driven by a 226% year-over-year revenue surge to $127.4 million in the first quarter. This growth was primarily attributed to increased sales of its DefenCath product and the newly acquired Melinta portfolio. The company also reported a non-recurring $9.0 million favorable adjustment related to sales allowances.AInvestCormedix 2Q EPS 29c, est. 24cCorMedix Inc. reported second-quarter earnings per share of $0.29, exceeding the estimated $0.24, driven by a surge in net revenue from its DefenCath product to $39.7 million. The company also announced the acquisition of Melinta Therapeutics LLC with a target closing date in September 2025. This performance marks a significant turnaround from a net loss in the same period last year.BenzingaCorMedix Stock Jumps As DefenCath Fuels Q1 Beat, 2026 Outlook Raised - Cormedix (NASDAQ:CRMD)CorMedix Therapeutics reported first-quarter net revenue of $127.4 million, up sharply from $39.1 million in the same period last year, beating consensus estimates of $105.02 million, driven by DefenCath sales of $97.5 million and contributions from the acquired Melinta anti-infective portfolio totaling $29.9 million. The company raised its 2026 net revenue guidance to $325 million-$345 million and adjusted EBITDA guidance to $115 million-$135 million. CorMedix also outlined pipeline progress, including plans to submit a supplemental NDA for REZZAYO to the FDA in the second half of 2026 and a Phase 3 study for taurolidine/heparin catheter lock solution on track for completion in 2028.Investing.comCorMedix stock surges 8% on raised guidance despite earnings miss By Investing.comCorMedix Therapeutics reported mixed first-quarter results on Thursday, beating revenue expectations with $127.4 million versus the $105.02 million estimate while missing adjusted EPS of $0.43 against a $0.45 consensus. The company's shares surged 8% in pre-market trading after it raised full-year 2026 revenue guidance to $325–$345 million, exceeding analyst consensus of $308.2 million, driven by strong DefenCath sales and the acquired Melinta portfolio. CorMedix also announced positive Phase III topline results for REZZAYO, with plans to submit an sNDA in the second half of 2026 for an expanded invasive fungal disease prophylaxis indication.openPR.comKey Strategic Developments and Emerging Changes Shaping the Carbapenem-Based Antibiotics Market LandscapeThe carbapenem-based antibiotics market is projected to reach $6.4 billion by 2030, growing at a compound annual growth rate of 6.2%, driven by rising antibiotic resistance and expanded healthcare access in emerging markets. In July 2023, Melinta Therapeutics LLC partnered with the Biomedical Advanced Research and Development Authority (BARDA), securing an initial $20.5 million in funding with potential to reach $141.9 million, to advance FDA-approved antibiotic candidates through supplemental new drug applications. Additionally, the UK's National Health Service launched an antibiotic subscription model in August 2024, offering fixed annual payments of up to $23.12 million per drug regardless of prescription volume to encourage responsible antibiotic use.Investing.comCorMedix at Leerink Conference: Strategic Evolution and Market Potential By Investing.comCorMedix Inc. presented at the Leerink Global Healthcare Conference 2026, with CEO Joseph Todisco outlining the company's strategic evolution following its 2025 acquisition of Melinta, positioning it as a multi-product specialty pharmaceutical company focused on institutional care settings. The discussion highlighted strong adoption of DefenCath in outpatient settings amid the TDAPA transition, the Phase 3 ReSPECT trial for REZZAYO in invasive fungal prophylaxis with data expected mid-to-late Q2, and a Phase 3 study for DefenCath in TPN targeted for early 2027 completion. The company emphasized financial stability with $150 million cash, zero net debt, and a $70 million stock repurchase program, while noting its valuation at 4.5x forward EBITDA compares unfavorably to peer valuations of 9-14x.Investing.comHigh Risk, High Reward: 3 Healthcare Stocks to Watch in 2026This article presents a curated watchlist of three healthcare/biotech stocks for 2026 investment: Atai Beckley developing a nasal spray for treatment-resistant depression, CorMedix focused on hemodialysis catheter solutions and recently acquired Melinta Therapeutics, and Evommune targeting atopic dermatitis through an IPO launched in November 2025. The analysis highlights Phase 2b trial data, upcoming Phase 3 trials, and acquisition-driven revenue boosts as key catalysts for each company amid improved biotech funding conditions driven by lower interest rates.DealformaInfectious R&D Partnerships, M&A and Venture FundingQ3 2025 marked a resurgence in infectious disease investments, with R&D partnerships totaling 11 deals worth $966 million, M&A activity surging to 7 transactions valued at $19.5 billion, and venture funding reaching $369 million across 12 rounds. Key M&A transactions included BD's $17.5 billion Reverse Morris Trust merger with Waters Corporation to form a combined diagnostics company, Sanofi's $1.2 billion acquisition of Vicebio for RSV and hMPV vaccines, and CorMedix's $300 million purchase of Melinta Therapeutics for approved antifungals and antibiotics.